Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HCRTR1 | O43613 | 11/20 | 0.35 |
| ▸ | HCRTR2 | O43614 | 6/20 | 0.34 |
| ▸ | GABRA5 | P31644 | 1/20 | 0.34 |
| ▸ | LIPE | Q05469 | 1/20 | 0.34 |
| ▸ | SCN9A | Q15858 | 2/20 | 0.33 |
| ▸ | GPR119 | Q8TDV5 | 2/20 | 0.33 |
| ▸ | HPGDS | O60760 | 1/20 | 0.33 |
| ▸ | ABHD6 | Q9BV23 | 1/20 | 0.32 |
| ▸ | DAGLA | Q9Y4D2 | 1/20 | 0.32 |
| ▸ | CNR2 | P34972 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4296862 | 0.94 | HCRTR1 (0.35) | HCRTR1HCRTR2LIPESCN9ACNR2 | |
| SCHEMBL13705264 | 0.92 | SYK (0.33) | HCRTR1HCRTR2GPR119HPGDSABHD6 | |
| SCHEMBL13705262 | 0.90 | HPGDS (0.33) | HCRTR1HCRTR2GABRA5GPR119HPGDS | |
| SCHEMBL13705266 | 0.90 | GPR119 (0.35) | HCRTR1HCRTR2GABRA5GPR119HPGDS | |
| SCHEMBL13705263 | 0.89 | IDH1 (0.36) | HCRTR1HCRTR2HPGDSABHD6DAGLA | |
| SCHEMBL13705256 | 0.88 | EGFR (0.35) | GPR119HPGDSABHD6DAGLA | |
| SCHEMBL13705261 | 0.88 | HPGDS (0.34) | HCRTR1HCRTR2HPGDSABHD6DAGLA | |
| SCHEMBL13705265 | 0.88 | SSTR4 (0.33) | ABHD6DAGLA | |
| SCHEMBL13705254 | 0.87 | HPGDS (0.36) | HCRTR1HCRTR2GPR119HPGDS | |
| SCHEMBL13705306 | 0.86 | HPGDS (0.35) | HCRTR1HCRTR2HPGDS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090227560-A1 | Substituted imidazole compound and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-09-10 | — | — | US | disclosed |
| US-20090156612-A1 | Substituted imidazole compound and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-06-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090156612-A1 | Substituted imidazole compound and use thereof | REN, ACE, AGT | HCRTR1 3147/4885HCRTR2 3136/4885GABRA5 1948/4885 |
| US-20090227560-A1 | Substituted imidazole compound and use thereof | REN, ACE, AGT | HCRTR1 3147/4885HCRTR2 3136/4885GABRA5 1948/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.